MDxHealth (MDXH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 32% year-over-year to $22.2 million, with H1 revenue up 34% to $42.0 million, driven by strong demand for precision diagnostics in urology markets and commercial execution.

• Tissue-based test volumes rose 15% and liquid-based test volumes increased 35% year-over-year in Q2, with both sales and managed care teams delivering results.

• CEO highlighted continued adoption and pricing strength for Confirm and GPS tests, supporting sustainable growth above 20%.

• Expanded test menu and market access contributed to performance.

Financial highlights

• Q2 2024 revenue reached $22.2 million, up 32% from Q2 2023; gross profit was $13.3 million, a 33% increase year-over-year, and gross margin was 60% in Q2 2024, compared to 59.7% in Q2 2023.

• Q2 operating loss reduced to $7.4 million from $7.7 million in Q2 2023; net loss increased 8% to $11.5 million due to $3.1 million in one-time debt extinguishment costs.

• Excluding debt extinguishment, Q2 net loss was $8.4 million, a 21% reduction year-over-year.

• Cash and cash equivalents stood at $21.3 million as of June 30, 2024.

Outlook and guidance

• 2024 revenue guidance raised to $85–$87 million, up from $79–$81 million, implying over 20% year-over-year top-line growth.

• Management reiterated confidence in achieving sustainable revenue growth of 20% or greater, citing expanded test menu and market opportunity.

• Hereditary germline test expected to contribute to revenue in the second half of 2024.